Concepedia

Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial

Thomas Powles, Toni K. Choueiri, Laurence Albigès, Katriina Peltola, Guillermo de Velasco, Mauricio Burotto, Cristina Suárez, Pooja Ghatalia, Roberto Iacovelli, Elaine T. Lam,

The Lancet Oncology · 2025 · 10 citations · 15 references

DOI

Concepts

References

15

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Robert J. Motzer, Bernard Escudier, Saby George et al. · New England Journal of Medicine · 2015 · 5.9K citations · Full text

, , +17

Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial

Robert J. Motzer, Thomas E. Hutson, Hilary Glen et al. · The Lancet Oncology · 2015 · 943 citations · Full text

, , +14

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

Toni K. Choueiri, Bernard Escudier, Thomas Powles et al. · The Lancet Oncology · 2016 · 939 citations · Full text

, , +12

Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

T. Powles, Laurence Albigès, Axel Bex et al. · Annals of Oncology · 2024 · 300 citations · Full text

, , +14

Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial

David Cella, Viktor Grünwald, Paul Nathan et al. · The Lancet Oncology · 2016 · 218 citations

, , +13